Authors
SY Brulé, DJ Jonker, CS Karapetis, Christopher J O’Callaghan, MJ Moore, R Wong, Niall C Tebbutt, Cr Underhill, D Yip, John R Zalcberg, D Tu, RA Goodwin
Publication date
2015/7/1
Journal
European journal of cancer
Volume
51
Issue
11
Pages
1405-1414
Publisher
Pergamon
Description
Background
Right- and left-sided colon cancers (RC, LC) differ with respect to biology, pathology and epidemiology. Previous data suggest a mortality difference between RC and LC. We examined if primary tumour side also predicts for outcome in chemotherapy refractory, metastatic colon cancer (MCC). We also compared RC versus LC as a predictor of efficacy of epidermal growth factor receptor (EGFR) inhibition with cetuximab.
Methods
Reanalyzing NCIC CO.17 trial (cetuximab versus best supportive care [BSC]), we coded the primary tumour side as RC (caecum to transverse colon) or LC (splenic flexure to rectosigmoid). The association between tumour side and baseline characteristics was assessed. Cox regression models determined factors affecting overall survival (OS) and progression free survival (PFS).
Results
Patients with RC (150/399) had more poorly differentiated, mutant KRAS, mutated PIK3CA …
Scholar articles
SY Brulé, DJ Jonker, CS Karapetis, CJ O'Callaghan… - European journal of cancer, 2015
SY Brulé, DJ Jonker, CS Karapetis, CJ O'Callaghan… - Yip D., Zalcberg CJ, Tu D., Goodwin RA Location of …